The incidence of rectal cancer, particularly among younger adults, has risen substantially over recent decades [1], prompting renewed focus on optimizing diagnostic and therapeutic strategies. Management has evolved from surgery alone to a multimodal approach integrating chemoradiation, total mesorectal excision (TME), and systemic chemotherapy. Landmark clinical trials have shaped current standards, demonstrating improvements in local control and disease-free survival. More recently, total neoadjuvant therapy (TNT) has redefined treatment sequencing by delivering all systemic therapy before surgery, enhancing tumor response and reducing distant metastases [8,9]. Additionally, organ-preserving approaches, including non-operative management for patients achieving a complete clinical response, are increasingly being explored [14,15]. This review summarizes the historical development of rectal cancer management, highlights pivotal clinical trials, and discusses emerging strategies that may further individualize therapy.